Related Experiment Video
Updated: May 11, 2026

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Propranolol-resistant infantile haemangiomas
S Caussé1, H Aubert, M Saint-Jean
1Department of Dermatology, Centre Hospitalier Universitaire Hôtel-Dieu, 1 place Alexis-Ricordeau, 44093 Nantes Cedex 1, France.
Background:
Propranolol is now widely used to treat severe infantile haemangiomas (IHs). Very few cases of propranolol-resistant IH (PRIH) are mentioned in the literature.
Objectives:
To describe the characteristics of PRIHs.
Methods:
A national, multicentre, retrospective, observational study was conducted from February 2011 to December 2011. All patients with PRIH evaluated by the members of the Groupe de Recherche Clinique en Dermatologie Pédiatrique from 1 January 2007 to 1 December 2011 were eligible.
Results:
Among 1130 patients treated with propranolol for infantile haemangioma, 10 (0.9%) had PRIHs. Haemangioma propranolol resistance was observed at all ages during early childhood and at any proliferation stage.
Conclusions:
PRIH is a rare phenomenon that raises questions and merits further investigation.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers

